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RUNX3 expression contributes to the development of HCC. We also demonstrate a novel 
mechanism by which the loss of RUNX3 reduces epithelial-mesenchymal transition via 
decreasing jagged-1 expression.  
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Abstract  
Loss or decreased expression of runt-related transcription factor 3 (RUNX3), a tumor 
suppressor gene involved in gastric and other cancers, has been frequently observed in 
hepatocellular carcinoma (HCC). The objective of this study was to identify the regulatory 
mechanism of the epithelial-mesenchymal transition (EMT) by RUNX3 in HCC. Human 
HCC cell lines, Hep3B, Huh7, HLF, and SK-Hep1, were divided into low- and high-EMT 
lines, based on their expression of TWIST1 and SNAI2, and were used in this in vitro study. 
Ectopic RUNX3 expression had an anti-EMT effect in low-EMT HCC cell lines 
characterized by increased E-cadherin expression and decreased N-cadherin and vimentin 
expression. RUNX3 expression has previously been reported to reduce JAG1 expression; 
therefore, JAG1 ligand peptide was employed to re-induce EMT in RUNX3-expressing 
low-EMT HCC cells. Immunohistochemical analyses were performed for RUNX3, 
E-cadherin, N-cadherin, and TWIST1 in 33 human HCC tissues, also divided into low- and 
high-EMT HCC, based on TWIST1 expression. E-cadherin expression was correlated 
positively and N-cadherin expression was correlated negatively with RUNX3 expression in 
low-EMT HCC tissues. Correlations between EMT markers and RUNX3 mRNA 
expression were analyzed using Oncomine datasets. Similarly, mRNA expression of 
E-cadherin was also significantly correlated with that of RUNX3 in low-EMT HCC, while 
mRNA expression of JAG1 was negatively correlated with that of RUNX3. These results 
suggest a novel mechanism by which loss or decreased expression of RUNX3 induces 
EMT via induction of JAG1 expression in low-EMT HCC.
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Introduction 
Hepatocellular carcinoma (HCC) is a human cancer with a high mortality rate worldwide 1-3. 
Although the prognosis for HCC has improved in recent years, the prognosis for advanced 
disease remains poor 4-9. Tumor progression in HCC is associated with altered expression 
of multiple molecules, including growth factors and their receptors, oncogenes, tumor 
suppressor genes, and transcription factors 1, 10. Gaining a better understanding of the 
molecular mechanisms underlying tumor progression would aid in the development of new 
therapies for advanced HCC. 
 
The epithelial-mesenchymal transition (EMT) is considered a critical event in the malignant 
transformation of cancer, especially during metastasis 11, 12. Several models demonstrating 
the contribution of EMT to the progression of established tumors in transformed cells have 
been developed 12-14, including HCC cells 15. Because EMT is characterized by loss of 
cell-cell adhesion and leads to cell individualization, EMT is known to be involved in 
increasing cell motility. Normally, adherent junctions connect cells via homotypic 
interactions mediated by E-cadherin molecules, the prototypic member of the cadherin 
superfamily. Not surprisingly, therefore, an inverse correlation has been found between 
expression of E-cadherin and the invasive capacity of a cell 16. The downregulation of 
E-cadherin expression is also a major hallmark of EMT and is closely related to the 
malignant progression of HCC. Loss of E-cadherin expression has been strongly implicated 
in the progression and metastasis of human cancers 17-19. In addition, abnormal expression 
of E-cadherin is a useful prognostic factor in patients with gastric carcinoma. E-cadherin 
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expression has also been found to be inversely correlated with the expression of certain 
transcription factors, including slug (SNAI2), snail (SNAI1), and twist homolog 1 
(TWIST1) 20-22. EMT is induced by several oncogenic pathways, including Src, Ras, Ets, 
integrin, transforming growth factor-β1, laminin 5, Wnt/β-catenin, and Notch 23-25. The 
process is induced by a complex orchestration of signaling cascades comprising many 
signaling pathways, making the understanding of its mechanism more challenging. 
 
The transcriptional factor TWIST1 has been shown to play a key role in EMT and 
metastasis in HCC 15, 20, and was originally identified as a master regulator of embryonic 
morphogenesis 26-28. Recent studies have also revealed that TWIST1-induced EMT 
enhances tumor metastasis 29, 30, and TWIST1 expression enhanced cell migration activity 
in HCC cell lines 15. Thus, here, HCC cell lines were divided into low- and high-EMT 
groups based on SNAI2 and TWIST1 expression. 
 
Runt-related transcription factor 3 (RUNX3) has been reported to be a tumor suppressor 
gene for gastric cancer 31. Therefore, it is not surprising that RUNX3 gene expression 
decreases in HCC and other human malignancies, including those of the colon, lung, 
pancreas, and bile duct 32-35. Several authors have reported that RUNX3 gene and protein 
expression is decreased in HCC and that loss of RUNX3 expression prevented apoptosis in 
HCC cells 36-39. We also reported that ectopic RUNX3 expression deactivated Notch 
signaling by decreasing jagged-1 (JAG1) expression in HCC 40. Based on the 
morphological changes in an HCC cell line with ectopic RUNX3 expression, we 
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hypothesized that RUNX3 increases cell-cell adhesion in HCC cells. In the present study, 
we demonstrate that the loss of RUNX3 protein expression results in an EMT-like change 
via increased expression of JAG1 in HCC. 
 
Material and Methods 
Cell lines and culture. The human HCC cell lines Hep3B, Huh7, HLF, and SK-Hep1 were 
obtained from the American Type Culture Collection (Manassas, VA). The cells were 
maintained in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA), 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma, St. Louis, MO), 
1% nonessential amino acids (Sigma), 1% sodium pyruvate (Sigma), and 1% 
penicillin/streptomycin solution (Sigma). The cells were cultured at 37 °C in an atmosphere 
of 5% CO2 and 95% air. The cells were quiesced at subconfluence under restricted serum 
conditions with 0.1% dialyzed FBS for 36 h before the experiment, if needed.  
 
Immunoblot analysis. Cells were plated in 6-well, plastic tissue culture dishes and grown 
to confluence. The cells were washed twice with cold phosphate-buffered saline (PBS) and 
lysed in 150 µL of sample buffer (100 mM Tris-HCl [pH 6.8], 10% glycerol, 4% sodium 
dodecyl sulfate [SDS], 1% bromophenol blue, and 10% β-mercaptoethanol). The samples 
were resolved by SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to an 
Immobilon-PTM polyvinylidene difluoride membrane (Millipore Corporation, Bedford, 
MA). The membranes were blocked using Tris-buffered saline with Tween 20 (TBS-T) 
(Sigma) buffer containing 5% bovine serum albumin for 1 h. The membranes were then 
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incubated with antibodies against SNAI2 (#9589; Cell Signaling Technology, Danvers, 
MA), TWIST1 (sc-6269; Santa Cruz Biotechnology Inc., Santa Cruz, CA), RUNX3 
(R3-G54; Abcam, Cambridge, MA), E-cadherin (#610181; BD Biosciences, San Diego, 
CA), N-cadherin (#05-915; Millipore), vimentin (ab8069; Abcam), and α-actin (Sigma) 
overnight at 4 °C. The membranes were washed 3 times with TBS-T and probed with 
horseradish peroxidase-conjugated secondary antibody before being developed with an 
ECL western blotting detection system (Amersham Biosciences, Piscataway, NJ) using 
enhanced chemiluminescence.  
 
RUNX3-expressing cell lines. The human RUNX3 construct was obtained by reverse 
transcriptase polymerase chain reaction (PCR)-based cloning from normal human 
hepatocytes 38. The human RUNX3 and/or chloramphenicol acetyltransferase (CAT) (mock) 
constructs were transfected into Hep3B, Huh7, HLF, or SK-Hep1 cells using the 
FuGeneTM6 transfection reagent (Roche Diagnostics, Basel, Switzerland), per the 
manufacturer’s instructions. Forty-eight hours after transfection, cells were grown in 
complete medium, containing 250 µg/mL hygromycin (Roche Diagnostics). Polyclonal 
lines consisting of >20 colonies were established. At least 2 independent transfections were 
performed for each cell line, with a transfection efficiency of more than 80%, as determined 
by immunocytochemistry using anti-CAT antibody and/or anti-RUNX3 antibody. After 
selection, all experiments were performed within 5 passages to avoid natural transformation 
and natural selection. The cells were cultured under serum-starved conditions for 24–36 h, 
if needed, and utilized in the following experiments.  
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Morphological analysis. Cells were plated onto 6-well, plastic tissue culture dishes with 
quiescent medium at a density of 105 cells/mL. After 24 h, morphological observations 
were made using phase-contrast microscopy (IMT-2; Olympus, Tokyo, Japan). 
 
Immunocytochemistry analysis. Cells were cultured in a glass chamber (Lab-Tek II; 
Nalgene Nunc, Roskilde, Denmark) to a density of approximately 2 × 105 cells/mL for 24 h, 
prior to being fixed for 20 min in 3% freshly hydrolyzed paraformaldehyde in PBS, at room 
temperature. After washing with PBS, the cells were incubated with anti-E-cadherin 
antibody (M3613, Dako Japan, Tokyo, Japan) for 30 min at room temperature, and 
visualized using Oregon Green-conjugated secondary antibody (Invitrogen). Photographs 
were taken using a fluorescence microscope (BX51, Olympus) equipped with a digital 
image capturing system (DP50, Olympus).  
 
MTT assay. Cell proliferation activity was assessed using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) assay. In 
brief, cells were grown in 96-well tissue culture dishes. After 24 h of quiescence, the cells 
were cultured for the indicated period with or without 10% FBS. At the end of the treatment, 
10 µL of MTT (5 mg/mL in PBS) was added to each well and incubated for an additional 4 
h at 37 °C. The purple-blue MTT formazan precipitate was dissolved in 100 µL of 
isopropanol/HCl (0.04 N). The activity of the mitochondria, reflecting cellular growth and 
viability, was evaluated by measuring the optical density at 570 nm with a microplate 
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reader (Bio-Rad, Hercules, CA).  
 
Cell migration assay. Cell migration was assessed using an in vitro wound healing assay. 
The cells were cultured in 6-well tissue culture dishes. After 24 h of quiescence, 
experimental wounds were made by dragging a rubber PolicemanTM (Fisher Scientific, 
Hampton, NH) across the cell culture. The cultures were rinsed with PBS and placed in 
fresh quiescence medium. The cells were treated with 10% FBS and/or caspase inhibitor 
(Caspase Inhibitor IV, 100 µM; Calbiochem, Gibbstown, NJ) for 24 h at 37 °C. Three 
wounds were created for each specimen. Photographs were taken at 0 and 24 h, and the 
relative distance traveled by the cells at the acellular front was determined.  
 
DAPI staining. Cells were grown to 50% confluence in a glass chamber (Lab-Tek II; 
Nalgene Nunc) and quiesced for 24 h. The cells were then treated with 10% FBS and/or 
caspase inhibitor IV (100 µM) for 24 h. Following exposure, chromosomal DNA was 
stained with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Dojindo, Kumamoto, 
Japan), at a concentration of 1 µg/mL in PBS for 2 min, according to the manufacturer’s 
protocol. The stained cells were then observed by fluorescence microscopy (IX-70; 
Olympus). 
 
Ectopic TWIST1 protein expression. Human TWIST1 cDNA was obtained by PCR-based 
cloning from a normal human placenta cDNA library (Takara Bio Inc., Otsu, Japan) and 
subcloned into the pcDNA 3.1 expression vector (Invitrogen) 15. TWIST1 and green 
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fluorescent protein (GFP; control) constructs were transfected into RUNX3-expressing 
Hep3B cells using FugeneTM6 (Roche Diagnostics). Cells were incubated for 48 h after 
transfection, after which immunoblot analyses and the cell migration assays were 
performed.  
 
JAG1 ligand treatment. Because RUNX3 expression deactivates Notch signaling by 
downregulating JAG1 expression 40, the JAG1 ligand peptide was employed to activate 
Notch signaling 41. RUNX3- or control CAT-expressing Hep3B cells were treated with or 
without 50 µM JAG1 ligand peptide (AnaSpec, Fremont, CA) and/or control-scrambled 
peptide for 48 h. Cells were then lysed and an immunoblot analysis was performed.  
 
HCC tissues and immunohistochemistry. A group of 33 patients, 24 men (age range, 
39–77 years; average age, 62.2 years), and 9 women, (age range, 54–82 years; average age, 
64.9 years), were included in this study. Resected HCC tissues were obtained after 
receiving written informed consent that adhered to the stringent ethical criteria of the 
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. 
Immunohistochemistry was performed on formalin-fixed paraffin sections prepared from 
the resected tissue. Sections were dewaxed and dehydrated; after rehydration, endogenous 
peroxidase activity was blocked for 30 min in a methanol solution containing 0.3% 
hydrogen peroxide. Following antigen retrieval in citrate buffer, the sections were blocked, 
again, overnight at 4 °C. The sections were probed with anti-RUNX3 rabbit polyclonal 
antibody (ab49117; Abcam), anti-E-cadherin monoclonal antibody (Dako Japan), 
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anti-N-cadherin monoclonal antibody (M3613; Dako Japan), anti-SNAI2 rabbit polyclonal 
antibody (#9585; Cell Signaling Technology), and anti-TWIST1 goat polyclonal antibody 
(Santa Cruz Biotechnology, Inc.). The primary antibody was detected using a biotinylated 
anti-rabbit antibody (Dako Japan) or a biotinylated anti-goat antibody (Dako Japan). The 
signal was amplified by avidin-biotin complex formation and was developed with 
diaminobenzidine, followed by dehydration in alcohol and xylene, and the sections were 
mounted. The sections were scored for RUNX3, E-cadherin, N-cadherin, and TWIST1 
expression using a 4-point scale: 0, negative; 1, weak signal; 2, intermediate signal; and 3, 
strong signal 42. All sections were scored independently by 2 observers, without prior 
knowledge of the clinical background. All discrepancies in scoring were reviewed and a 
consensus was reached. Because TWIST1 is a major EMT inducer and an indicator 43, 
TWIST1-positive (score 2 or 3) HCCs were designated as high-EMT HCCs, while 
TWIST1-negative (score 0 or 1) HCCs were designated as low-EMT HCCs. The 
clinicopathological features, TWIST1, and RUNX3 expression levels are shown in the 
Supplemental Table 1. Statistical analyses were performed using JMP software (SAS 
Institute Inc., Cary, NC). 
 
Gene expression profiling analysis in human HCC. To further investigate correlations 
between RUNX3 expression and transcriptional regulation of E-cadherin, N-cadherin, and 
vimentin, JAG1 expression profiles in low-EMT HCCs from publicly available HCC data 
sets were evaluated using Oncomine (hppt://www.oncomine.org). In brief, after excluding 
TWIST1-positive (high-EMT) (TWIST1/213943_at > -0.20) HCCs from the Chiang Liver 
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data sets, mRNA expression profiles for RUNX3, E-cadherin, N-cadherin, vimentin, and 
JAG1 were evaluated using RUNX3/234928_x_at, CDH1/201130_s_at, CDH2/203440_at, 
VIM/155938_x_at, and JAG1/231183_s, respectively. Statistical analyses were performed 
using JMP software (SAS Institute Inc.).  
 
Results 
EMT-inducer expression in HCC cell lines. HCC cell lines were divided into 2 groups 
according to SNAI2 and TWIST1 expression: Hep3B and Huh7 cells were designated as 
low-EMT cells, and HLF and SK-Hep1 cells as high-EMT cells (Fig. 1). Low-EMT cells 
expressed E-cadherin, while no detectable level of E-cadherin was found in high-EMT 
cells. 
 
Ectopic RUNX3 expression in HCC cell lines. Ectopic RUNX3 expression was evaluated 
in endogenous RUNX3-negative HCC cell lines 38, and the morphological changes were 
analyzed under phase-contrast microscopy. Ectopic RUNX3 expression changed the 
morphology of the cells from a fibroblast-like spindle shape to a paving stone, sheet-like 
structure in Hep3B (Fig. 2A) and Huh7 cells (Supplemental Fig. 1). These cells showed 
well-organized cell-cell adhesion, characteristic of epithelial cells. E-cadherin expression 
was enhanced in the RUNX3-expressing Hep3B cells (Fig. 2B) or Huh7 cells (data not 
shown), especially at the cell-cell junction. In contrast, RUNX3 expression did not induce 
significant morphological changes in HLF (Fig. 2A) or SK-Hep1 cells (Supplemental Fig. 
1), neither was E-cadherin expression significantly different in these cells (Fig. 2B). 
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RUNX3 protein expression was also confirmed in RUNX3 cDNA-transfected cells (Fig. 
2C).  
 
Ectopic RUNX3 protein expression inverted EMT in HCC cell lines. E-cadherin, 
N-cadherin, and vimentin expression were assessed by immunoblot analysis in HCC cell 
lines (Fig. 2C). E-cadherin expression was induced by ectopic RUNX3 protein expression 
in low-EMT cells. High-EMT HCC cells did not express E-cadherin, and ectopic RUNX3 
protein expression did not induce E-cadherin expression and it had little effect on 
N-cadherin and vimentin expression in high-EMT HCC cells. However, ectopic RUNX3 
protein expression suppressed N-cadherin and vimentin expression in low-EMT HCC cells.  
 
Ectopic RUNX3 protein expression suppressed cell growth under serum starvation. To 
confirm the biological effects of ectopic RUNX3 protein expression, MTT assays were 
performed to determine the effect on cell proliferation. In all 4 HCC cell lines, RUNX3 
expression suppressed cell growth by 31–38% (Fig. 2D).  
 
Ectopic RUNX3 protein expression suppressed cell migration in HCC cell lines. The 
effect of ectopic RUNX3 expression on HCC cell lines was examined in the in vitro wound 
healing assay, which is commonly used to assess the effects of pro- and anti-migratory 
agents on cultured cells. RUNX3 expression significantly suppressed cell migration by 
70% ± 20% and 63% ± 5% in Hep3B and Huh7 cells, respectively, but not in HLF and 
SK-Hep1 cells (Fig. 2E). 
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Effect of RUNX3 expression on cell migration in the presence of an apoptosis inhibitor. 
An apoptosis inhibitor was used to determine if apoptosis-inducing factors affected cell 
migration activity in ectopic RUNX3 protein-expressing HCC cell lines. Caspase inhibitor 
IV was observed to inhibit serum starvation-induced apoptosis by 74% in 
RUNX3-expressing Hep3B cells (Fig. 3A). However, caspase inhibitor IV did not abrogate 
the RUNX3-induced reduction in cell migration activity in these cells (Fig. 3B).  
 
TWIST1 expression abrogated the anti-EMT effect of ectopic RUNX3. RUNX3 appeared 
to have a weak effect on EMT in TWIST1-positive HCC cell lines. To determine if ectopic 
TWIST1 expression affects the anti-EMT effect of RUNX3 expression, TWIST1 cDNA 
was introduced into the TWIST1-negative HCC cell line Hep3B, causing the cells to 
transiently express TWIST1 (Fig. 4A). RUNX3 expression did not have a significant effect 
on the EMT markers, E-cadherin, N-cadherin, or vimentin in TWIST1-expressing Hep3B 
cells (Fig. 4A). Likewise, RUNX3 expression did not have the anti-migratory effect on 
TWIST1-expressing Hep3B cells (Fig. 4B).  
 
JAG1 expression. The JAG1 ligand peptide was used to determine if RUNX3 expression is 
regulated via JAG1. The JAG1 ligand peptide decreased E-cadherin expression in 
RUNX3-expressing Hep3B cells (Fig. 5) and induced re-expression of N-cadherin and 
vimentin in RUNX3-expressing Hep3B cells (Fig. 5).  
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E-cadherin expression correlation with RUNX3 expression in HCC tissues. Thirty-three 
HCC tissue samples were available for comparing E-cadherin and RUNX3 protein 
expression by immunohistochemistry. Representative images of E-cadherin-negative (Score 
0), E-cadherin-positive (Score 3), N-cadherin-negative (Score 0), and N-cadherin-positive 
(Score 3) tissues are shown in Figs. 6A-a, b, c, and d, respectively. To determine if there 
was a relationship between E-cadherin and RUNX3 expression in HCC tissues, the scores 
for E-cadherin immunoreactivity were plotted against those for RUNX3 (Fig. 6B). In 
general, low E-cadherin expression scores were observed in tissues with low RUNX3 
expression. Statistical analysis revealed that RUNX3 expression and E-cadherin expression 
were significantly correlated (r = 0.58, P = 0.0025) in low-EMT HCC tissues. Scores for 
N-cadherin immunoreactivity were also plotted against those for RUNX3 (Fig. 6C), where 
high N-cadherin expression scores were observed in tissues with low RUNX3 expression. A 
significant inverse correlation was found between RUNX3 and N-cadherin expression (r = 
-0.74, P < 0.0001). Thus, high-EMT HCC tissues showed low expression of E-cadherin and 
high expression of N-cadherin.  
 
Gene expression profiling analysis in human HCC. A further examination of the 
correlation between expression of RUNX3 and of EMT markers was conducted by 
analyzing the Oncomine datasets. These analyses revealed that JAG1 mRNA expression 
was negatively correlated with RUNX3 mRNA expression in low-EMT HCC tissues (r = 
0.28, P < 0.05) (Fig. 6D). E-cadherin mRNA expression was also found to be significantly 
correlated with RUNX3 mRNA expression in low-EMT HCC tissues (r = 0.33, P < 0.05) 
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(Fig. 6D). mRNA expressions of N-cadherin and vimentin tended to be negatively 
correlated with RUNX3 mRNA expression, but the correlations were not significant (r = 
-0.24 and -0.07, respectively) (Fig. 6D).  
 
Discussion 
RUNX3 expression is generally reduced in human HCC tissues 36, 38. However, the role of 
decreased RUNX3 expression in the development and progression of HCC has not yet been 
fully elucidated. The results obtained here suggest that decreased expression of the RUNX3 
protein contributes to induction of EMT in HCC cell lines.  
 
Ectopic RUNX3 expression was evaluated in the endogenous RUNX3-negative HCC cell 
lines Hep3B, Huh7, HLF, and SK-Hep1 (Fig. 2C). The establishment of 
RUNX3-expressing cell lines was advantageous in order to elucidate the RUNX3-related 
molecular mechanism, as they helped to provide additional clarity to the results obtained. 
RUNX3 expression is known to cause apoptosis, especially in the absence of FBS 38, 
whereas RUNX3-expressing cells can grow in the presence of FBS. Because RUNX3 is a 
strong apoptosis inducer 38, 44, the anti-cell migratory effect of RUNX3 could be due to the 
apoptosis enhanced by serum starvation. Therefore, a caspase inhibitor was employed to 
eliminate the potential effects of apoptosis on cell migration. The caspase inhibitor 
successfully abrogated RUNX3-induced apoptosis (Fig. 3A), but RUNX3-expressing cells 
did not recover their cell migration activity (Fig. 3B). Morphological studies also showed 
that ectopic RUNX3 expression induced phenotypic changes, resulting in the cells adopting 
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a more plate-like shape instead of their normal, spindle-like shape, in the low-EMT HCC 
cell lines, but not in the high-EMT HCC cell lines. These results are consistent with the cell 
shapes generally associated with migratory and non-migratory cells. Collectively, these 
results suggest that RUNX3 is directly connected to the inhibition of cellular migration 
associated with metastatic cells. 
 
Several studies examined the downregulation of E-cadherin in HCCs by 
immunohistochemical analyses 44-46. In accordance with these reports, E-cadherin 
expression was generally reduced in human HCC tissues and was correlated with RUNX3 
expression (Fig. 6B). The strong correlation between RUNX3 and E-cadherin expression 
suggests that loss of RUNX3 expression may cause reduced E-cadherin expression. 
Similarly, RUNX3 was only able to induce E-cadherin expression in low-EMT HCC cell 
lines (Fig. 2B, 2C). As TWIST1 is a strong inducer of EMT and reduces E-cadherin 
expression, RUNX3 had no effect on E-cadherin expression and very little effect on 
N-cadherin and vimentin expression in high-EMT cells (Fig. 2C). But, N-cadherin and 
vimentin expression were reduced by ectopic RUNX3 expression in low-EMT HCC cells. 
Expression of N-cadherin was also analyzed in human HCC tissues. N-cadherin expression 
was inversely related to RUNX3 expression in low-EMT HCC tissues (Fig. 6C).  
 
The effects of TWIST1 expression on RUNX3-expressing HCC cell lines were examined 
by transiently expressing the TWIST1 protein in TWIST1-negative Hep3B cells by 
transfecting TWIST1 cDNA into CAT- and RUNX3-expressing Hep3B cells (Fig. 4A). 
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Ectopic RUNX3 protein expression did not have a significant effect on the EMT markers 
and cell migration activity in TWIST1-expressing cells (Fig. 4B). Although there is a 
possibility that TWIST1 and RUNX3 independently act on E-cadherin, N-cadherin, and 
vimentin expression, the present results suggest that TWIST1 is the more important 
regulator of these EMT markers. Therefore, a sequence of genetic alterations in the 
progression of EMT in HCC may be hypothesized based on the frequency of gene 
alteration in HCC. The loss of RUNX3 protein expression was found in ~90% of HCC 
tissue samples, while TWIST1 expression was found in ~30% of HCC tissue samples 15, 38. 
Recently, Aleksic et al. also reported that loss of RUNX3 was a frequent, early event in 
chemical liver carcinogenesis 47. Various authors have reported that a loss of or decreased 
expression of RUNX3 is generally found in HCC 37-39, suggesting that decreased expression 
of RUNX3 could be an early event in human HCC. Since TWIST1 expression reduced 
RUNX3 expression (Fig. 4A), TWIST1 may interact with RUNX3 to progress EMT in 
HCC. Further studies are needed to elucidate the detailed mechanism of interaction 
between RUNX3 and TWIST1 expression. 
 
RUNX3 has also been previously reported to regulate JAG1 expression in HCC cells by 
suppressing transcription through direct binding to the transcriptional regulatory region of 
JAG1 40. To clarify whether RUNX3 regulates EMT in HCC cells through JAG1 expression, 
the JAG1 ligand peptide was employed. The JAG1 ligand peptide successfully re-induced 
EMT in RUNX3-expressing Hep3B cells (Fig. 5).  
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Because a relatively small number of HCC tissues were analyzed for RUNX3 and EMT 
marker expression using immunohistochemistry, Oncomine datasets were also analyzed for 
RUNX3 mRNA expression and the mRNA of EMT markers in low-EMT HCCs (Fig. 6D). 
In accordance with both a previous report 40 and the present results, JAG1 mRNA 
expression was significantly, negatively correlated with RUNX3 mRNA expression (Fig. 
6D) and E-cadherin mRNA expression was significantly correlated with RUNX3 mRNA 
expression (Fig. 6D). Although significant correlations were not found between RUNX3 
mRNA expression and the other EMT markers, N-cadherin mRNA expression and vimentin 
mRNA expression tended to be inversely related to RUNX3 mRNA expression.  
 
A repressive function of EMT has been found in a study of tumor suppressor genes in 
which depletion of a retinoblastoma protein induced EMT in a breast cancer cell line 48. 
The present study suggests that other tumor suppressor genes may be similarly involved in 
EMT. A relationship between RUNX3 expression and EMT was reported by Chang et al., 
who demonstrated that RUNX3 expression induced claudin expression 49. The regulatory 
function of EMT by RUNX3 was also predicted in a prospective review 50. Herein, we 
demonstrated that RUNX3 expression regulates EMT through JAG1 expression.  
 
Conclusions 
We uncovered a novel function of RUNX3 in regulating EMT in HCC. Our results suggest 
that loss or decreased expression of RUNX3 induced EMT via inducing JAG1 expression.  
Page 19 of 37 International Journal of Cancer
20 
 
 
 
Acknowledgments 
The authors wish to thank Tatsuya Fujikawa for valuable suggestions. 
 
Financial support: This work is supported by a grant-in-aid from the Japan Society for the 
Promotion of Science (Grant #23590975). 
 
Potential conflict of interest: Nothing to report. 
 
 
Page 20 of 37International Journal of Cancer
21 
 
 
 
References 
 1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular 
carcinogenesis. Gastroenterol 2007;132:2557-76. 
 2. Garcia M, Jernal A, Ward EM, Center MM, Hao Y, Siegel RI, Thun MJ, Global Cancer 
Facts & Figures 2007,.2007; Society AC. Atlanta, GA 
 3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 
2000. Int J Cancer 2001;94:153-6. 
 4. Kaizu T, Karasawa K, Tanaka Y, Matuda T, Kurosaki H, Tanaka S, Kumazaki T. 
Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective 
study of 57 patients. Am J Gastroenterol 1998;93:2167-71. 
 5. Patt YZ, Claghorn L, Charnsangavej C, Soski M, Cleary K, Mavligit GM. 
Hepatocellular carcinoma. A retrospective analysis of treatments to manage disease 
confined to the liver. Cancer 1988;61:1884-8. 
 6. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. 
Prognostic features, treatment outcome, and survival. Cancer 1996;77:2217-22. 
 7. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver 
cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1984;54:970-7. 
 8. Doci R, Bignami P, Bozzetti F, Bonfanti G, Audisio R, Colombo M, Gennari L. 
Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 
1988;61:1983-7. 
 9. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, 
Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to 
treatment. Study of 850 patients. Cancer 1985;56:918-28. 
 10. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Molec Med 
2003;3:573-88. 
 11. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell 
2001;105:425-31. 
 12. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature reviews 
2002;2:442-54. 
 13. Laffin B, Wellberg E, Kwak HI, Burghardt RC, Metz RP, Gustafson T, Schedin P, 
Porter WW. Loss of singleminded-2s in the mouse mammary gland induces an 
epithelial-mesenchymal transition associated with up-regulation of slug and matrix 
metalloprotease 2. Molec Cell Biol 2008;28:1936-46. 
Page 21 of 37 International Journal of Cancer
22 
 
 
 
 14. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal 
transition during tumor progression. Curr Opinion Cell Biol 2005;17:548-58. 
 15. Matsuo N, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Tanaka S, Nishina S, 
Nakanishi Y, Uemura M, Takaki A, Nakamura S, Kobayashi Y, et al. Twist expression 
promotes migration and invasion in hepatocellular carcinoma. Cancer 2009;9:240. 
 16. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier 
W. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma 
cells. J Cell Biol 1991;113:173-85. 
 17. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, 
Debruyne FM, Isaacs WB. Expression of the cellular adhesion molecule E-cadherin is 
reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9. 
 18. Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, 
Hansen B, Devilee P, Cornelisse CJ. At least two different regions are involved in 
allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes 
Cancer 1994;9:101-7. 
 19. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, 
Isaacs WB. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc 
Nat Acad Sci USA 1990;87:8751-5. 
 20. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, 
Man K, Chau KL, Fan ST. Twist overexpression correlates with hepatocellular 
carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin 
Cancer Res 2006;12:5369-76. 
 21. Jiao W, Miyazaki K, Kitajima Y. Inverse correlation between E-cadherin and Snail 
expression in hepatocellular carcinoma cell lines in vitro and in vivo. Br J Cancer 
2002;86:98-101. 
 22. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr 
Opinion Cell Biol 2003;15:740-6. 
 23. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal 
transitions. Biochem Pharmacol 2000;60:1091-9. 
 24. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with 
transforming growth factor-beta1 induces epithelial to mesenchymal transition in 
hepatocellular carcinoma. Gastroenterol 2005;129:1375-83. 
 25. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, Machat G, 
Page 22 of 37International Journal of Cancer
23 
 
 
 
Grubinger M, Huber H, Mikulits W. Epithelial-mesenchymal transition in 
hepatocellular carcinoma. Future Oncol 2009;5:1169-79. 
 26. Chen ZF, Behringer RR. twist is required in head mesenchyme for cranial neural tube 
morphogenesis. Genes Devel 1995;9:686-99. 
 27. Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA. TWIST, a basic 
helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell 
Biochem 1999;75:566-77. 
 28. Thisse B, el Messal M, Perrin-Schmitt F. The twist gene: isolation of a Drosophila 
zygotic gene necessary for the establishment of dorsoventral pattern. Nucleic Acids Res 
1987;15:3439-53. 
 29. Vernon AE, LaBonne C. Tumor metastasis: a new twist on epithelial-mesenchymal 
transitions. Curr Biol 2004;14:R719-21. 
 30. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, 
Gitelman I, Richardson A, Weinberg RA. Twist, a master regulator of morphogenesis, 
plays an essential role in tumor metastasis. Cell 2004;117:927-39. 
 31. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee 
CW, Han SB, Kim HM, Kim WJ, et al. Causal relationship between the loss of RUNX3 
expression and gastric cancer. Cell 2002;109:113-24. 
 32. Araki K, Osaki M, Nagahama Y, Hiramatsu T, Nakamura H, Ohgi S, Ito H. Expression 
of RUNX3 protein in human lung adenocarcinoma: Implications for tumor progression 
and prognosis. Cancer Sci 2005;96:227-31. 
 33. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO, Park JG. 
Promoter hypermethylation downregulates RUNX3 gene expression in colorectal 
cancer cell lines. Oncogene 2004;23:6736-42. 
 34. Li J, Kleeff J, Guweidhi A, Esposito I, Berberat PO, Giese T, Buchler MW, Friess H. 
RUNX3 expression in primary and metastatic pancreatic cancer. J Clin Pathol 
2004;57:294-9. 
 35. Wada M, Yazumi S, Takaishi S, Hasegawa K, Sawada M, Tanaka H, Ida H, Sakakura 
C, Ito K, Ito Y, Chiba T. Frequent loss of RUNX3 gene expression in human bile duct 
and pancreatic cancer cell lines. Oncogene 2004;23:2401-07. 
 36. Li X, Zhang Y, Qiao T, Wu K, Ding J, Liu J, Fan D. RUNX3 Inhibits growth of HCC 
cells and HCC xenografts in mice in combination with adriamycin. Cancer Biol Ther 
2008;7:669-76. 
Page 23 of 37 International Journal of Cancer
24 
 
 
 
 37. Mori T, Nomoto S, Koshikawa K, Fujii T, Sakai M, Nishikawa Y, Inoue S, Takeda S, 
Kaneko T, Nakao A. Decreased expression and frequent allelic inactivation of the 
RUNX3 gene at 1p36 in human hepatocellular carcinoma. Liver Int 2005;25:380-8. 
 38. Nakanishi Y, Shiraha H, Nishina SI, Tanaka S, Matsubara M, Horiguchi S, Iwamuro 
M, Takaoka N, Uemura M, Kuwaki K, Hagihara H, Toshimori J, et al. Loss of 
runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to 
escape apoptosis. BMC Cancer 2011;11:3. 
 39. Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in 
hepatocellular carcinoma. World J Gastroenterol 2004;10:376-80. 
 40. Nishina S, Shiraha H, Nakanishi Y, Tanaka S, Matsubara M, Takaoka N, Uemura M, 
Horiguchi S, Kataoka J, Iwamuro M, Yagi T, Yamamoto K. Restored expression of the 
tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma 
by suppressing Jagged1-Notch signaling. Oncol Rep 2011;26:523-31. 
 41. Weijzen S, Velders MP, Elmishad AG, Bacon PE, Panella JR, Nickoloff BJ, Miele L, 
Kast WM. The Notch ligand Jagged-1 is able to induce maturation of 
monocyte-derived human dendritic cells. J Immunol 2002;169:4273-8. 
 42. Ng IO, Chung LP, Tsang SW, Lam CL, Lai EC, Fan ST, Ng M. p53 gene mutation 
spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene 
1994;9:985-90. 
 43. Savagner P, Yamada KM, Thiery JP. The zinc-finger protein slug causes desmosome 
dissociation, an initial and necessary step for growth factor-induced 
epithelial-mesenchymal transition. J Cell Biol 1997;137:1403-19. 
 44. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of 
the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. 
Proc Nat Acad Sci USA 1995;92:7416-9. 
 45. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M, Hirohashi S. The 
E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. 
Int J Cancer 1997;71:355-9. 
 46. Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by 
genetic and epigenetic changes in the malignant progression of hepatocellular 
carcinomas. Clin Cancer Res 2001;7:594-9. 
 47. Aleksic K, Lackner C, Geigl JB, Schwarz M, Auer M, Ulz P, Fischer M, Trajanoski Z, 
Otte M, Speicher MR. Evolution of genomic instability in diethylnitrosamine-induced 
Page 24 of 37International Journal of Cancer
25 
 
 
 
hepatocarcinogenesis in mice. Hepatol 2011;53:895-904. 
 48. Arima Y, Inoue Y, Shibata T, Hayashi H, Nagano O, Saya H, Taya Y. Rb depletion 
results in deregulation of E-cadherin and induction of cellular phenotypic changes that 
are characteristic of the epithelial-to-mesenchymal transition. Cancer Res 
2008;68:5104-12. 
 49. Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG, Fukamachi H, Ito Y. 
Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric 
epithelial cells. Gastroenterol 2010;138:255-65 e1-3. 
 50. Shiraha H, Nishina SI, Yamamoto K. Loss of runt-related transcription factor 3 causes 
development and progression of hepatocellular carcinoma. J Cell Biochem 
2011;112:745-49. 
 
 
Page 25 of 37 International Journal of Cancer
26 
 
 
 
Figure Legends 
 
Fig. 1. Expression of epithelial-mesenchymal transition (EMT) inducers in hepatocellular 
carcinoma (HCC) cell lines. Immunoblot analyses were performed using antibodies against 
SNAI2, TWIST1, and E-cadherin. Immunoblotting for α-actin levels was used to verify 
equal loading of cellular proteins. HCC cell lines were divided into 2 groups according to 
EMT-inducer SNAI2 and TWIST1expression. Representative blots of more than 3 
independent experiments are shown. 
 
Fig. 2. Ectopic RUNX3 protein expression in hepatocellular carcinoma (HCC) cell lines. 
Eukaryotic expression constructs for CAT (mock) and RUNX3 were introduced into Hep3B, 
Huh7, HLF, and SK-Hep1 cell lines. After a 24-h quiescence, cells were used for the 
experiments in the presence of 10% FBS. (A) Micrographs were taken by phase-contrast 
microscopy. The micrographs are representative of 3 independent experiments. Bar = 100 
µm. (B) Immunocytochemical analysis was performed using antibody against E-cadherin. 
The micrographs are representative of 3 independent experiments. Bar = 40 µm. (C) 
Immunoblot analyses were performed using antibodies against RUNX3, E-cadherin, 
N-cadherin, and vimentin. Immunoblotting for α-actin levels was used to verify equal 
loading of cellular proteins. Representative blots of more than 3 independent studies are 
shown. (D) Cell proliferation activity was measured by MTT assay (mock, white bars; 
RUNX3, black bars). (E) Cell migration activity was measured as described in the Material 
and Methods (mock, white bars; RUNX3, black bars). (D, E) All results were normalized to 
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cell proliferation and migration activity for CAT-expressing Hep3B cells. Data represent the 
mean ± SE of more than 3 independent experiments, each performed in triplicate. n.s., P > 
0.05; *, P < 0.05; **, P < 0.01 (versus data for mock-transfected Hep3B); Student’s t test.  
 
Fig. 3. Effect of an apoptosis inhibitor. Hep3B cells were cultured on glass chamber slides 
and quiesced, then treated with or without caspase inhibitor IV (100 µM) and 10% fetal 
bovine serum. (A) Apoptosis was quantified using the DAPI apoptosis detection assay 
(mock, white bars; RUNX3, black bars). Results are expressed as percent apoptotic cells. 
Data represent the mean ± SE of more than 3 independent experiments, each performed in 
triplicate. n.s., P > 0.05; **, P < 0.01 (versus data for mock-transfected cells); Student’s t 
test. (B) Cell migration activities were measured as described in the Material and Methods 
(mock, white bars; RUNX3, black bars). All results are normalized to data for untreated 
control cells. Data represent the mean ± SE of more than 3 independent experiments, each 
performed in triplicate. n.s., P > 0.05; *, P < 0.05; **, P < 0.01 (versus data for 
mock-transfected cells); Student’s t test. 
 
Fig. 4. Effect of TWIST1 expression on epithelial-mesenchymal transition (EMT) markers. 
CMV-driven eukaryotic expression constructs for green fluorescent protein (GFP; control) 
and TWIST1 were introduced into CAT- and RUNX3- expressing Hep3B. (A) Cell lysates 
were collected 48 h after transfection. Immunoblot analyses were performed using 
antibodies against RUNX3, TWIST1, E-cadherin, N-cadherin, and vimentin. 
Immunoblotting for α-actin levels was used to verify equal loading of cellular proteins. 
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Representative blots of more than 3 independent experiments are shown. (B) Cell migration 
activities were measured as described in the Material and Methods (mock, white bars; 
RUNX3, black bars). Results are normalized to data for GFP (control) transfected 
CAT-expressing Hep3B cells. Data represent the mean ± SE of more than 3 independent 
experiments, each performed in triplicate. n.s., P > 0.05; **, P < 0.01 (versus data for 
mock-transfected cells); Student’s t test.  
 
Fig. 5. Effect of JAG1 stimulation on epithelial-mesenchymal transition (EMT) markers. 
CMV-driven eukaryotic expression constructs for green fluorescent protein (GFP; control) 
and TWIST1 were transfected into CAT- and/or RUNX3- expressing Hep3B. Cell lysates 
were collected 48 h after transfection. Immunoblot analyses were performed using 
antibodies against RUNX3, E-cadherin, N-cadherin, and vimentin. Immunoblotting for 
α-actin levels was used to verify equal loading of cellular proteins. Representative blots of 
more than 3 independent experiments are shown. 
 
Fig. 6. Correlations between RUNX3 expression and epithelial-mesenchymal transition 
(EMT) markers in human HCC  
(A) The images show the immunohistochemical staining of E-cadherin (a, protein score of 
0; b, protein score of 3) and N-cadherin (c, protein score of 0; d, protein score of 3). Bar = 
100 µm. 
(B,C) RUNX3, E-cadherin, N-cadherin, and TWIST1 protein expression were assessed by 
immunohistochemical analysis in human HCC tissues and corresponding tumor-free 
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sections. Plots of the E-cadherin (B) and N-cadherin (C) expression score are shown 
compared with the RUNX3 expression score. (D) Correlations between RUNX3 expression 
and EMT markers were analyzed using publicly available microarray data sets 
(www.oncomine.org). RUNX3, E-cadherin, N-cadherin, vimentin, and JAG1 expression are 
plotted. The data are shown as arbitrary expression values. A 95% tolerance ellipse for each 
pair of variables was calculated and plotted.  
 
Supplemental Fig. 1. Morphological study of RUNX3-expressing hepatocellular carcinoma 
(HCC) cell lines. Eukaryotic expression constructs for CAT (mock) and RUNX3 were 
introduced into Huh7 and SK-Hep1 cell lines. After a 24-h incubation, micrographs were 
taken by phase-contrast microscopy. The micrographs are representative fields from 3 
independent experiments. Bar = 100 µm.  
 
 
Page 29 of 37 International Journal of Cancer
  
 
 
Fig. 1. Expression of epithelial-mesenchymal transition (EMT) inducers in hepatocellular carcinoma 
(HCC) cell lines. Immunoblot analyses were performed using antibodies against SNAI2, TWIST1, 
and E-cadherin. Immunoblotting for α-actin levels was used to verify equal loading of cellular 
proteins. HCC cell lines were divided into 2 groups according to EMT-inducer SNAI2 and 
TWIST1expression. Representative blots of more than 3 independent experiments are shown.  
125x98mm (300 x 300 DPI)  
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Fig. 2. Ectopic RUNX3 protein expression in hepatocellular carcinoma (HCC) cell lines. Eukaryotic 
expression constructs for CAT (mock) and RUNX3 were introduced into Hep3B, Huh7, HLF, and SK-
Hep1 cell lines. After a 24-h quiescence, cells were used for the experiments in the presence of 10% 
FBS. (A) Micrographs were taken by phase-contrast microscopy. The micrographs are 
representative of 3 independent experiments. Bar = 100 µm. (B) Immunocytochemical analysis was 
performed using antibody against E-cadherin. The micrographs are representative of 3 independent 
experiments. Bar = 40 µm. (C) Immunoblot analyses were performed using antibodies against 
RUNX3, E-cadherin, N-cadherin, and vimentin. Immunoblotting for α-actin levels was used to verify 
equal loading of cellular proteins. Representative blots of more than 3 independent studies are 
shown. (D) Cell proliferation activity was measured by MTT assay (mock, white bars; RUNX3, black 
bars). (E) Cell migration activity was measured as described in the Material and Methods (mock, 
white bars; RUNX3, black bars). (D, E) All results were normalized to cell proliferation and migration 
activity for CAT-expressing Hep3B cells. Data represent the mean ± SE of more than 3 independent 
experiments, each performed in triplicate. n.s., P > 0.05; *, P < 0.05; **, P < 0.01 (versus data for 
mock-transfected Hep3B); Student’s t test.  
204x206mm (300 x 300 DPI)  
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Fig. 3. Effect of an apoptosis inhibitor. Hep3B cells were cultured on glass chamber slides and 
quiesced, then treated with or without caspase inhibitor IV (100 µM) and 10% fetal bovine serum. 
(A) Apoptosis was quantified using the DAPI apoptosis detection assay (mock, white bars; RUNX3, 
black bars). Results are expressed as percent apoptotic cells. Data represent the mean ± SE of 
more than 3 independent experiments, each performed in triplicate. n.s., P > 0.05; **, P < 0.01 
(versus data for mock-transfected cells); Student’s t test. (B) Cell migration activities were 
measured as described in the Material and Methods (mock, white bars; RUNX3, black bars). All 
results are normalized to data for untreated control cells. Data represent the mean ± SE of more 
than 3 independent experiments, each performed in triplicate. n.s., P > 0.05; *, P < 0.05; **, P < 
0.01 (versus data for mock-transfected cells); Student’s t test.  
178x278mm (300 x 300 DPI)  
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Fig. 4. Effect of TWIST1 expression on epithelial-mesenchymal transition (EMT) markers. CMV-
driven eukaryotic expression constructs for green fluorescent protein (GFP; control) and TWIST1 
were introduced into CAT- and RUNX3- expressing Hep3B. (A) Cell lysates were collected 48 h after 
transfection. Immunoblot analyses were performed using antibodies against RUNX3, TWIST1, E-
cadherin, N-cadherin, and vimentin. Immunoblotting for α-actin levels was used to verify equal 
loading of cellular proteins. Representative blots of more than 3 independent experiments are 
shown. (B) Cell migration activities were measured as described in the Material and Methods (mock, 
white bars; RUNX3, black bars). Results are normalized to data for GFP (control) transfected CAT-
expressing Hep3B cells. Data represent the mean ± SE of more than 3 independent experiments, 
each performed in triplicate. n.s., P > 0.05; **, P < 0.01 (versus data for mock-transfected cells); 
Student’s t test.  
223x247mm (300 x 300 DPI)  
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Fig. 5. Effect of JAG1 stimulation on epithelial-mesenchymal transition (EMT) markers. CMV-driven 
eukaryotic expression constructs for green fluorescent protein (GFP; control) and TWIST1 were 
transfected into CAT- and/or RUNX3- expressing Hep3B. Cell lysates were collected 48 h after 
transfection. Immunoblot analyses were performed using antibodies against RUNX3, E-cadherin, N-
cadherin, and vimentin. Immunoblotting for α-actin levels was used to verify equal loading of 
cellular proteins. Representative blots of more than 3 independent experiments are shown.  
87x76mm (300 x 300 DPI)  
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Fig. 6. Correlations between RUNX3 expression and epithelial-mesenchymal transition (EMT) 
markers in human HCC  
(A) The images show the immunohistochemical staining of E-cadherin (a, protein score of 0; b, 
protein score of 3) and N-cadherin (c, protein score of 0; d, protein score of 3). Bar = 100 µm. 
(B,C) RUNX3, E-cadherin, N-cadherin, and TWIST1 protein expression were assessed by 
immunohistochemical analysis in human HCC tissues and corresponding tumor-free sections. Plots 
of the E-cadherin (B) and N-cadherin (C) expression score are shown compared with the RUNX3 
expression score. (D) Correlations between RUNX3 expression and EMT markers were analyzed 
using publicly available microarray data sets (www.oncomine.org). RUNX3, E-cadherin, N-cadherin, 
vimentin, and JAG1 expression are plotted. The data are shown as arbitrary expression values. A 
95% tolerance ellipse for each pair of variables was calculated and plotted.  
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Supplemental Fig. 1. Morphological study of RUNX3-expressing hepatocellular carcinoma (HCC) cell 
lines. Eukaryotic expression constructs for CAT (mock) and RUNX3 were introduced into Huh7 and 
SK-Hep1 cell lines. After a 24-h incubation, micrographs were taken by phase-contrast microscopy. 
The micrographs are representative fields from 3 independent experiments. Bar = 100 µm.  
163x112mm (300 x 300 DPI)  
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Supplemental Table 1  TWIST1 and RUNX3 expression levels and 
clinicopathological features. 
 
EMT (TWIST1) Low High 
RUNX3 expression 
score 
0 1  2  3   
Number 12 10 2 1 8 
pTNM stage      
Stage I 2 1 0 0 2 
Stage II 1 6 1 0 4 
Stage IIIA 9 3 1 1 2 
Stage IIIB 0 0 0 0 0 
Stage IV 0 0 0 0 0 
Distant metastasis      
M0 12 10 2 1 8 
M1 0 0 0 0 0 
Portal vein invasion      
Absent 8 9 2 1 5 
Present 4 1 0 0 3 
 
 
 
Page 37 of 37 International Journal of Cancer
